Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Conditions
Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Contact: Study coordinator (Ambuga Badari)University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles, California, United States
UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Northside Hospital, Atlanta, Georgia, United States
Northwestern Memorial Hospital, Chicago, Illinois, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Contact: Study coordinator (Jennifer Cooperrider)University of Iowa, Iowa City, Iowa, United States
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
Norton Women's and Children's Hospital, Louisville, Kentucky, United States
Local Institution - 0065, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of North Carolina Medical Center, Chapel Hill, North Carolina, United States
Local Institution - 0067, Charlotte, North Carolina, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
Tennessee Oncology, Nashville, Tennessee, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Local Institution - 0069, Austin, Texas, United States
UT Southwestern Medical Center, Dallas, Texas, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio, Texas, United States
LDS Hospital, Salt Lake City, Utah, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
St Vincent's Hospital, Melbourne, Victoria, Australia
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
McGill University Health Centre, Montreal, Quebec, Canada
Nagoya City University Hospital, Nagoya, Aichi-ken, Japan
Hyogo Medical University Hospital, Nishinomiya, Hyōgo, Japan
Chiba University Hospital, Chiba, Japan
University Hospital,Kyoto Prefectural University of Medicine, Kyoto, Japan
Japanese Red Cross Medical Center, Tokyo, Japan
Study leads
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb